PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23082898-1	2012	OBJECTIVES: The once-daily prolonged-release formulation of tacrolimus (tacrolimus QD) is expected to demonstrate equivalent efficacy and safety to the twice-daily formulation (tacrolimus BID).	Tacrolimus	60-70	BH3 interacting domain death agonist	Homo sapiens	188-191	
23082898-10	2012	CONCLUSIONS: Patients taking tacrolimus QD tended to have lower trough levels and require higher dosages than those taking tacrolimus BID during the early posttransplant period, though the differences decreased with increasing time after transplant.	Tacrolimus	123-133	BH3 interacting domain death agonist	Homo sapiens	134-137